It has been demonstrated that STING agonists can inhibit the growth and proliferation of breast cancer cells and can be used not only in the treatment of breast cancer, but also in combination with atenrizumab to enhance the efficacy of immunotherapy [57]. This evidence concerns the gene STING1 and breast carcinoma.